Hillhurst Biopharmaceuticals, Inc.
Liberating patients from the burden of sickle cell disease
Montrose, United States · Founded 2015 · $2.0M raised
- Headquarters
- Montrose, California
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- hillhurstbio.com
- Total Funding
- $2.0M
- Last Round
- $2.0M GrantMay 2025
- Rounds
- 4
About
Hillhurst Biopharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral therapies for sickle cell disease and related conditions. Its proprietary GLASS platform enables oral delivery of therapeutic agents that are safer and more convenient for at-home administration. The company's lead candidate HBI-002 targets sickle cell disease and Parkinson's disease, with a follow-on non-opioid compound targeting acute pain.
Summary
Hillhurst Biopharmaceuticals, Inc. is a Biotech company based in Montrose, United States, founded in 2015. It has raised $2.0M in total across 4 rounds, most recently a $2.0M Grant round in May 2025. Investors include National Institutes of Health and Michael J. Fox Foundation.
Tech & App Stack
2 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
May 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...